Soriano-Maldonado Alberto, Martínez-Forte Sonia, Ferrer-Márquez Manuel, Martínez-Rosales Elena, Hernández-Martínez Alba, Carretero-Ruiz Alejandro, Villa-González Emilio, Barranco-Ruiz Yaira, Rodríguez-Pérez Manuel A, Torrente-Sánchez María José, Carmona-Rodríguez Lorena, Soriano-Maldonado Pablo, Vargas-Hitos José A, Casimiro-Andújar Antonio J, Artero Enrique G, Fernández-Alonso Ana M
Department of Education, Faculty of Education Sciences; and SPORT Research Group (CTS-1024), CERNEP Research Center, University of Almería.
Obstetrics and Gynecology Unit, Torrecárdenas University Hospital, Almería.
Medicine (Baltimore). 2020 Mar;99(12):e19427. doi: 10.1097/MD.0000000000019427.
Severe and morbid obesity are increasing globally, particularly in women. As BMI increases, the likelihood of anovulation is higher. The primary aim of the EMOVAR clinical trial is to examine, over the short (16 weeks) and medium (12 months) term, the effects of a supervised physical exercise program (focused primarily on aerobic and resistance training) on ovarian function in women with severe/morbid obesity who have undergone bariatric surgery. Secondary objectives are to examine the effects of the intervention on chronic inflammation, insulin resistance, arterial stiffness, physical fitness, and health-related quality of life.
This is a randomized controlled trial in which ∼40 female bariatric surgery patients, aged between 18 and 45 years old, will be included. Participants assigned to the experimental group will perform a total of 48 sessions of supervised concurrent (strength and aerobic) training (3 sessions/week, 60 min/session) spread over 16 weeks. Patients assigned to the control group will receive lifestyle recommendations. Outcomes will be assessed at baseline, week 16 (i.e., after the exercise intervention) and 12 months after surgery. The primary outcome is ovarian function using the Sex-Hormone Binding Globuline, measured in serum. Secondary outcomes are serum levels of anti-mullerian hormone, TSH, T4, FSH, LH, estradiol, prolactine, and free androgen index, as well as oocyte count, the diameters of both ovaries, endometrial thickness, and uterine arterial pulsatility index (obtained from a transvaginal ultrasound), the duration of menstrual bleeding and menstrual cycle duration (obtained by personal interview) and hirsutism (Ferriman Gallwey Scale). Other secondary outcomes include serum markers of chronic inflammation and insulin resistance (i.e., C-reactive protein, interleukin 6, tumor necrosis factor-alpha, leptin, glomerular sedimentation rate, glucose, insulin and the HOMA-IR), arterial stiffness, systolic, diastolic and mean blood pressure, body composition, and total weight loss. Physical fitness (including cardiorespiratory fitness, muscular strength, and flexibility), health-related quality of life (SF-36 v2) and sexual function (Female Sexual Function Index) will also be measured.
This study will provide, for the first time, relevant information on the effects of exercise training on ovarian function and underlying mechanisms in severe/morbid obese women following bariatric surgery.
ISRCTN registry (ISRCTN27697878).
全球范围内,重度肥胖和病态肥胖的人数正在增加,尤其是女性。随着体重指数(BMI)的升高,无排卵的可能性也更高。EMOVAR临床试验的主要目的是在短期(16周)和中期(12个月)内,研究一项有监督的体育锻炼计划(主要侧重于有氧运动和抗阻训练)对接受过减肥手术的重度/病态肥胖女性卵巢功能的影响。次要目标是研究该干预措施对慢性炎症、胰岛素抵抗、动脉僵硬度、体能和健康相关生活质量的影响。
这是一项随机对照试验,将纳入约40名年龄在18至45岁之间的接受减肥手术的女性患者。分配到实验组的参与者将在16周内总共进行48节有监督的同时进行(力量和有氧)训练课程(每周3节,每节60分钟)。分配到对照组的患者将接受生活方式建议。在基线、第16周(即运动干预后)和手术后12个月评估结果。主要结果是使用血清中测量的性激素结合球蛋白来评估卵巢功能。次要结果是抗苗勒管激素、促甲状腺激素、甲状腺素、促卵泡激素、促黄体生成素、雌二醇、催乳素和游离雄激素指数的血清水平,以及卵母细胞计数、双侧卵巢直径、子宫内膜厚度和子宫动脉搏动指数(通过经阴道超声获得)、月经出血持续时间和月经周期持续时间(通过个人访谈获得)以及多毛症(费里曼-盖尔韦评分量表)。其他次要结果包括慢性炎症和胰岛素抵抗的血清标志物(即C反应蛋白、白细胞介素6、肿瘤坏死因子-α、瘦素、肾小球沉降率、葡萄糖、胰岛素和稳态模型评估胰岛素抵抗指数)、动脉僵硬度、收缩压、舒张压和平均血压、身体成分和总体重减轻。还将测量体能(包括心肺功能、肌肉力量和柔韧性)、健康相关生活质量(SF-36 v2)和性功能(女性性功能指数)。
本研究将首次提供有关运动训练对减肥手术后重度/病态肥胖女性卵巢功能及其潜在机制影响的相关信息。
国际标准随机对照试验编号注册库(ISRCTN27697878)。